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Abstract
Background: An aging population and better management of various heart diseases explain the exponential
growth in incidence and prevalence of chronic heart failure, with poor prognosis and heavy health costs. Medical
management is codified in international guidelines. The management of heart failure in over-80 year-old patients
follows these guidelines, but no clinical trials have been able to confirm benefit. Moreover, registries show down-
prescription of heart failure treatments in the elderly and over-80s.
Methods/Design: We present the design of the HF-80 ("Is there benefit in optimising heart failure treatment in
over-80 year-old patients?”) study, which is a prospective randomised open-label clinical trial with blinded end-
points, designed to evaluate the effect of optimising management by adhering to guidelines in over-80 year-old
heart failure patients. Patients over 80 years of age admitted with acute heart failure will be included. The primary
endpoint is to assess quality of life at 6 months on the Minnesota questionnaire. The secondary endpoints are to
assess the effect of optimised management on quality of life, mortality, readmission for acute heart failure, cardiac
fibrosis and economic data at 12 months. 80 patients will be included, divided into 2 groups: group A, with usual
heart failure management by general practitioners; and group B, with optimised management based on
international guidelines.
Discussion: It is necessary to assess the benefit of guidelines in over-80 year-old heart failure patients because of
the fragility of this population and the elevated risk of iatrogenic complications.
Trial Registration: Clinical trials.gov number: NCT01437371.
Keywords: Heart failure, Aged and over 80, clinical trial, quality of life
Background
An aging population and improved management of var-
ious heart diseases involving ischemic aetiologies explain
the growth in incidence and prevalence of chronic heart
failure (HF) [1], with high complication rates [2,3] and
heavy costs (more than 1% of total health care costs in
industrialised countries). Mean age at diagnosis of HF
was 70 years in the Framingham cohort [3]. Incidence
and prevalence increase exponentially with age [3].
Angiotensin-converting enzyme inhibitors (ACEi) [4,5]
beta-blockers [6,7], mineralocorticoid receptor antago-
nists [8], and angiotensin receptor blockers [9,10] pro-
vide first-line therapeutic management of HF as
recommended in international guidelines [11,12]. These,
however, are based on studies conducted on younger
patients (mean age between 61 and 71 years: Table 1).
Clinical management of over-80 year-old HF patients
conforms to these guidelines, but no clinical trials have
been able to confirm their benefit in this population.
Comorbidity and iatrogenic complications may impair
the effect of common treatments. Recent clinical trials
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jects, because of the need to highlight a beneficial effect
of the treatment tested [13-15]. Some studies have
reported benefit with such treatments in this kind of
population [16,17]. Registries and observational studies
highlighted down-prescription, especially for ACEi and
beta-blockers, in elderly and over-80 year-old patients
[18,19].
Methods/Design
Heart failure management is now clearly codified for the
general population, thanks to several studies and guide-
lines. Management of over-80 year-old HF patients,
however, is simply extrapolated from their findings. No
study has specifically assessed optimised HF treatment
in the over-80s, where potential benefit could be coun-
terbalanced by co-morbidity and iatrogenic complica-
tions. The HF-80 clinical trial was designed as a pilot
study to investigate whether optimised management has
an effect on quality of life (QOL) in over-80 year-old
HF patients.
The HF-80 Study
Objectives and endpoints
The primary objective of this pilot study is to assess
optimised HF management, according to the guidelines
of the European Society of Cardiology (ESC) [11,12], in
terms of impact on QOL in over-80 year-old patients at
6 months.
The secondary objectives are to evaluate the effect of
optimised management on:
￿ Quality of life at 12 months
￿ Mortality at 12 months
￿ Readmission for acute HF at 12 months
￿ Cardiovascular events at 12 months
￿ Cardiac fibrosis, evaluated by collagen peptides.
The primary assessment criterion is QOL at 6 months,
assessed on the Minnesota Living with Heart Failure
Questionnaire (LHFQ) [20].
The secondary assessment criteria are QOL at 12
months, measured by both the SF 12 [21] and LHFQ
[20] (to check which scale is most suited to this popula-
tion), mortality at 12 months, number of readmissions
for acute HF, cardiovascular events at 12 months, evolu-
tion in New York Hospital Association (NYHA) class (at
baseline, 6 months and 12 months), and evolution in 6-
minutes walking test (6MWT) (at baseline, 6 months
and 12 months). Finally, an analysis of the medical and
economic interest of this support will be conducted.
This pilot study will also help lay the groundwork for
a French national multicentre study of the management
of octogenarian HF patients to find what support is
most appropriate.
Study design
The HF-80 pilot study is a prospective randomised sin-
gle-centre open-label clinical trial with blinded
Table 1 Mean age of main studies in HF management
Clinical studies Ages of placebo Group (years old) Ages of studied drug group (years old)
HF subgroup of Hyvet (hypertension study) 83.5 ± 3.1 83.6 ± 3.2
Seniors 76.1 ± 4.8 76.1 ± 4.8
Charm-Alternative 66.8 ± 10.5 66.3 ± 11
Merit HF 63.7 63.9
Charm-Added 64.1 ± 11.3 64.0 ± 10.7
Consensus 71
Solvd 59.1 59.1
Cibis II 61 61
Emphasis-HF 68.6 ± 7.6 68.7 ± 7.7
Ephesus 66 ± 12 64 ± 11
Rales 65 ± 12 65 ± 12
Atlas study Low-dose of lisinopril: 63.6 ± 10.3 High-dose of lisinopril: 63.6 ± 10.5
Elite-1 trial Losartan: 74(5-8) Captopril: 73 (6-1)
Elite-II trial Losartan: 71.4 (6-7) Captopril: 71 (6-9)
Shift 60.1 ± 11.5 60.7 ± 11.2
Copernicus 63.4 ± 11.5 63.2 ± 11.4
Valiant Captopril: 64.9 ± 11.8
Valsartan: 65 ± 11.8
Valsartan + Captopril: 64.6 ± 11.9
Dig 63.9 ± 11.7 63.8 ± 11
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agement for this population requires a pilot study, to
harvest data before starting a clinical trial to assess mor-
tality. The study population is over-80 year-old patients
recently admitted for acute HF. Inclusion and exclusion
criteria are listed in Table 2.
Dementia will be assessed by the Mini mental state
examination (MMSE): patients with scores under 24/30
will not be included. For the very elderly, a preliminary
walking test will be performed, to exclude patients with
reduced mobility, who are moreover very often subject
to dementia.
Randomisation
Included patients will be randomly allocated to either
arm in a 1:1 ratio. The randomisation list is generated
by minimisation [22] to maintain better balance than
with traditional block randomisation. Stratification will
be performed on gender (female/male), readmission
(yes/no) and residence (ath o m e / n o ta th o m e ) .W h e na
patient is considered eligible and informed consent has
been obtained, randomisation will be performed auto-
matically (on software) by an independent statistician.
Investigation Procedure
Over-80 year-old patients will be recruited and rando-
mised into 2 groups of 40 (Figure 1):
￿ Group A: “usual care” management by the patient’s
usual general practitioner (GP) and cardiologist;
￿ Group B: “optimised” management strictly adher-
ing to ESC guidelines [11,12], performed by the
patient’s usual GP and cardiologist plus day-hospital.
Patients will be included in HF-80 at discharge from
acute HF care. Before inclusion, trans-thoracic echocar-
diography will confirm that left ventricle ejection frac-
tion is under 35% and that no exclusion criteria are
present. During hospital care, patients of both groups
will receive the same treatments, so far as possible using
all HF therapeutics; different hospital treatment accord-
ing to group would not be ethically acceptable. Mean
hospital stay is about 10 days, which is too short to
induce bias, as medical management optimisation
applies only after discharge. Optimised management will
be assessed with long-term prognosis.
An identical assessment is to be performed at baseline
and at 12 months for all patients (groups A and B) (Fig-
ure 2):
￿ Clinical examination: NYHA class; weight; height;
heart rate; blood pressure; right, left or both HF
symptoms; triggering factor; cardiovascular risk fac-
tors; thyroid pathologies; personal cardiovascular
history;
￿ Quality of life questionnaires (LHFQ [20], SF 12
[21]);
￿ Six-minutes walking test (6MWT);
￿ Electrocardiogram (EKG);
￿ Transthoracic echocardiography (TTE);
￿ Blood test (haemoglobin, kaliaemia, natraemia,
liver assessment, bilirubin, Modification in Diet
Table 2 Inclusion and exclusion criteria in HF 80 study
Inclusion criteria:
Aged over-80 year-old subjects
Hospitalized for an acute heart failure
Left Ventricle Ejection Fraction ≤ 35%
Evaluated life expectancy (Seattle Heart failure score) > 1 year
Exclusion criteria:
Dementia (evaluated by MMSE)
Do not understand French language
Followed with an optimized management
With reduced mobility
Recruited in another clinical trial or in a HF management network
Acute HF with curable aetiology: cardiovascular surgery for coronary artery bypass graft or valvular replacement, angioplasty
MDRD < 30 ml/min/1.73 m
2
Figure 1: Flow chart describing HF 80 study design 
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Figure 1 Flow chart describing HF 80 study design.H F :h e a r t
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Page 3 of 8Renal Disease (MDRD) [23], N-Terminal of pro-
Brain Natriuretic Peptide (NT-pro-BNP), and nutri-
tional tests (C-reactive protein, albumin, prealbumin
and orosomucoid);
￿ Renin, aldosterone and collagen peptides [type 1
collagen telopeptide (ICTP), aminoterminal propep-
tide of type I procollagen (PINP), aminoterminal
propeptide of type III procollagen (PIIINP)], and
galectin 3;
￿ Mini mental state examination (MMSE) [24].
During primary hospital care for acute HF and at dis-
charge, both groups will have the same management
with initiation of the same treatments, following guide-
lines [11,12].
Group A subjects will be followed up by their usual
GP and cardiologist without any day-hospital care
("usual care” management). The GP and cardiologist will
manage treatment optimisation as they are used to
doing.
Group B subjects will have the same management as
group A but will also receive day-hospital care. The first
3 visits will be at 3 weekly intervals, except in case of
unstable HF, and then every 6 weeks for 12 months, to
optimise treatment.
During each day-hospital visit in group B, certain data
will be recorded to optimise HF management:
￿ Clinical examination (NYHA class, HF symptoms,
blood pressure, heart rate);
￿ Blood sample (kaliaemia, MDRD [23], NT-pro-
BNP);
￿ Electrocardiogram;
￿ Optimised treatment doses, if possible, for ACEi,
beta-blockers, angiotensin receptor blocker and
mineralocorticoid receptor antagonist.
All the visits and contents are described in Table 3.
Patients in both groups will have a notebook, for 12
months. GPs and cardiologists will note all changes in
treatment and management.
Figure 2: Flow chart describing HF 80 study investigational procedure 
Figure 2 Flow chart describing HF 80 study investigational procedure. CE: clinical examination; EKG: electrocardiogram; MMSE: mini mental
state examination; QOL: quality of life scale; 6MWT: 6 minutes walking test; Seattle HF: Seattle heart failure score; TTE: transthoracic
echocardiography.
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TTE will be performed using a 2.5 MHz probe (VIVID
9, General Electrics), by a single operator [25], at inclu-
sion and at 12 months, in both groups. TTE will also be
performed at 3, 6 and 9 months for group B in day hos-
pital, and according to “usual management” criteria for
group A.
The following measurements will be taken in each
subject:
2D/MM modes: Right ventricle (RV) diameter (mm);
interventricular septum thickness at end diastole and
end systole (mm); left ventricle (LV) posterior wall
thickness at end diastole and end systole (mm); LV dia-
meter at end diastole and end systole (mm); LV volumes
at end diastole and end systole (ml); LV ejection fraction
measured by the biplane Simpson method (%); LV mass
index (g/m2); inferior vena cava diameter (mm); left and
r i g h ta t r i u ma r e a s( c m
2); RV volume; RV ejection frac-
tion; TEI myocardial performance index; and tricuspid
annular plane systolic excursion (TAPSE).
Doppler modes: transmitral flow, including peak E
wave (cm/s), peak A wave (cm/s), E/A ratio, E-wave
deceleration time (m/s); pulmonary venous waveforms,
including peak systolic (S) velocity, peak anterograde
diastolic (D) velocity, and S/D ratio; VP, Color M-Mode
flow propagation velocity; relaxation isovolumic time
(m/s); cardiac output, tricuspid E wave; tricuspid regur-
gitation (none/mean/moderate/severe); systolic pulmon-
ary arterial pressure; mitral regurgitation (none/mean/
moderate/severe); and dp/dt for left and right ventricle.
Doppler tissue imaging mode: lateral and septal E’
wave and A wave at mitral annulus (cm/s), lateral and
septal S wave at mitral annulus (cm/s); S’ and E’ wave at
tricuspid annulus (cm/s).
2D-Strain mode: Loops obtained by 2D on 3 cycles,
with apical 4-cavities, 3-cavities, 2-cavities and paraster-
nal short axis views, with frame rate > 60 frames/s.
6-minutes walking test
This will be performed for each patient at inclusion and
at 12 months, and also at 6 months for group B [26].
The test will be made in hospital on a 60-metre track.
The patients will be requested to walk at their tolerance
threshold for 6 minutes. Before the beginning of each
test, respiratory frequency, heart rate, blood pressure
and effort perception on the Borg scale [27,28] will be
measured. At the end of each test, the same parameters
will be measured again. The final result of the 6MWT is
the total distance covered (metres) in 6 minutes.
Blood tests
The usual blood tests made during acute HF hospitali-
sation will be performed by the hospital biochemistry
laboratory: haemoglobin, K, Na, liver assessment, bilir-
u b i n ,M D R D[ 2 3 ] ,N T - p r o - B N P ,n a t r i u r e s i s ,a n dn u t r i -
tional tests (C-reactive protein, albumin, prealbumin
and orosomucoid), using the AutomateVista 1500 (Sie-
mens HealthCare Diagnostics)]. Renin (Liaison Direct
Renin kit, Diasorin), aldosterone (ELISA Kit
(E90911Hu), USC N Life Science Inc.), PIIINP (ELISA
Kit (E90573Hu), USC N Life Science Inc.), PINP
(ELISA Kit (E90957Hu), USC N Life Science Inc.),
ICTP (ELISA Kit (E90665Hu), USC N Life Science
Inc.) and galectin 3 (ELISA kit (DGAL30), R and D
systems) will be analysed at end of trial, after storage
at -80°C.
Table 3 Schedule of visits and contents
Group A Group B
Enrollement
hospitalization
Month 12
visit
Enrollement
hospitalization
Day hospital
visits
Month 3
visit
Month 6
visit
Month 9
visit
Month 12
visit
QOL questionnaires
(LVHQ, SF12)
XX X X X
Clinical examination (BP, HR,
weight, NYHA)
XX XX X X X
E K G X X X X XXXX
6MWT X X X X
Na, Hb, SGOT, SGPT, Bili X X X X
K, MDRD, NT-pro-BNP X X X X XXXX
PCR, oroso, alb, prealb X X X X
T T E X X X XXXX
Blood laboratory X X X XXXX
Treatments X X X X XXXX
BP: blood pressure; HR: heart rate; EKG: electrocardiogram; MMSE: mini mental state examination; QOL: quality of life; 6MWT: 6 minutes walking test; Seattle HF:
Seattle heart failure score; TTE: transthoracic echocardiography; CRP: C reactive protein; oroso: orosomucoid; alb: albumin; prealb: prealbumin; MDRD:
Modification in Diet Renal Disease; NT-ProBNP: N terminal pro brain natriuretic peptid; K: kaliemia; Na: sodium blood concentration; Hb: hemoglobin; bili: biliubin;
SGPT: Serum Glutamopyruvate Transferase, SGOT: Serum Glutamooxaloacetate Transferase.
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It was decided to implement two QOL questionnaires
(LHFQ [20] and SF 12[21]) to assess which is more
adapted to over-80 year-old HF patients. Both are well-
validated and widely used. The SF12 is used on a daily
basis in the geriatric department of our hospital and
maybe more adapted to the elderly. A second endpoint
is to assess the efficiency of this shorter QOL question-
naire, SF12, as compared to the LHFQ, in a very elderly
population. They will be completed at inclusion and at
12 month for each subject. QOL scales will be sent to
all participants (group A and B) at 6 months (before the
6 month visit for group B) and will be filled in by the
patients without any help from medics or paramedics
(to avoid bias).
Statistical Considerations
Due to lack of information in the literature concerning
the management of over-80 year-old HF patients, it is
difficult to estimate correct sample size. The number of
subjects to be included is extrapolated from data
obtained on younger patients, according to which 40
subjects per group will be included.
With a 2-tailed significance threshold of 0.05, statisti-
cal power of 90% and allowing for 15% loss to follow-
up, 80 patients will be needed to show a difference of
20 points (s = 25) in quality of life (LHFQ) at 6 months
between the 2 randomisation arms [29]. Morcillo et al.
demonstrated that a 20-point difference in LFHQ is sig-
nificant and feasible in such a population at 6 months’
follow-up. An interim analysis is planned. For 34 evalu-
able patients (17 per group), a difference in QOL score
between the 2 arms will be considered significant for an
adjusted a equal to 0.003 (Lan and DeMets, EaSt
© soft-
ware). Termination for futility can thus be considered.
The number of patients included and the curve of the
inclusions, the theoretical number of visits for the num-
ber of patients included, the number of visits actually
made and the ratio will be presented for the 2 groups.
The cumulative duration of follow-up and the “total fol-
low-up/expected cumulative follow-up” ratio will be
calculated.
All analyses will be performed on an intention-to-treat
basis. Clinically relevant baseline variables and primary
and secondary endpoints will be compared between
groups by Chi
2 or Fisher-exact tests (categorical vari-
ables) and by Student’s t tests or Mann-Whitney tests as
appropriate (continuous variables). Multivariate analyses
to control for confounding effects of variables will be
performed.
The survival analysis will be conducted in univariate
analysis by log-rank test to compare survival curves fol-
lowing Kaplan-Meier, and in multivariate analysis by the
Cox proportional regression model.
To measure the evolution of parameters over time
points (visits), longitudinal data analysis will be con-
ducted by ANOVA for repeated measures followed by
Tukey-Kramer post-hoc test and by random effects
models to measure within-subject correlation taking
account of effects over time (random intercept and
slope). The impact of covariates, such as randomisation
group, will be explored to assess the impact of strategies
on QOL score.
Treatment compliance will be analysed initially in a
descriptive step and, if necessary, included in multivari-
ate analysis.
A 2-tailed p value of 0.05 will be considered statisti-
cally significant (except in interim analysis). All analyses
will be performed by STATAv11 (StataCorp, College
Station, Texas, USA).
Discussion
The aging of the population [1] is increasing hospital
admission for acute HF, particularly in subjects over 80
years of age. This is a special population, often with
multiple comorbidity and a high risk of iatrogenic com-
plications, in whom it is difficult to implement all
recommended treatments at optimal doses. There is a
significant difference between the optimal treatment
doses according to the literature on HF and the doses
actually prescribed to inpatients [18,19,30]. Guidelines
are extrapolated to this population without knowing
whether there is benefit.
Unfortunately, clinical trials on HF have recruited
young patients. Clinical studies in cardiology, and par-
ticularly in HF, recruit young subjects at the expense
of seniors who are underrepresented if not excluded
[31-33]. This trend was confirmed by recent large stu-
dies of therapeutic drugs (Emphasis-HF [13] and
SHIFT [14] subjects were aged, respectively, 68 and 60
years) and electric therapy [15]. The SENIORS study
[17] confirmed the value of beta-blockers in patients
over 70 years old; benefit, however, was especially pro-
nounced in patients younger than 75 years. The ELITE
study [34] was probably the first large HF trial to
decide to exclude young patients: only over-65 year-
olds were recruited, two-thirds aged 70 or older; the
safety of losartan and captopril in HF was demon-
strated. These findings were confirmed in morbidity
and mortality, but in a younger population (over-60
year-old HF patients [35]. HYVET [16], an antihyper-
tensive clinical trial, included patients over 80 years of
age and showed benefit with medical treatment in
hypertension in this age group, including in the sub-
group with onset of HF (64% reduction). Observational
studies and registries show down-prescription of
recommended treatments, including ACEi and beta-
blockers, in over-80 year-old HF patients [18,19,30].
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years old) to consider the respective interest of differ-
ent classes and recommended therapeutic doses. Given
the aging population and the exponential prevalence of
over-80 year-old HF patients, it is primordial to know
if optimised management with increased treatment
doses shows benefit in this population. Iatrogenic com-
plications such as chronic renal failure, orthostatic
hypotension or hyperkaliemia could aggravate clinical
status in this population and counterbalance expected
benefit. The ATLAS study confirmed that intermediate
and high-dose lisinopril was more effective in terms of
death and hospital admission than low doses, but with
side effects (dizziness, hypotension, worsening renal
function, hyperkaliaemia), although not such as to lead
to termination of lisinopril [36].
A potential bias is present in this design. Patients in
the “optimised” g r o u pw i l lh a v em o r ec a r d i o l o g yd a y -
hospital visits; GPs will be in charge of their own man-
agement optimisation, as recommended in the ESC
guidelines.
Divergent data are present in the literature on elderly
HF patients, and there is no consensus on managing
over-80 year-old patients. The growing size of this
population requires clinical trials to confirm that the HF
management validated in younger subjects is also effec-
tive in those over 80 years of age.
Trial Status
HF-80 study is in an activating recruiting phase since
October 2011. Institute’s committee on human research
(CPP Sud Est VI) agreement was obtained in April
2011. Subjects will give their informed consent before
being enrolled in the study. AFFSAPS agreement was
obtained in May 2011. HF-80 will start enrolling
patients in October 2011. Study completion date is esti-
mated at December 2012. Clinical trials.gov number:
NCT 01437371.
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